Timothy H Selfand Milap C Nahata ASTHMA is a common condition affecting 1 in 25 Americans and over 100millionpeople worldwide.r? It is associated with much human suffering and a huge economic toll with regard to institutional acute care and lost work and schooldays. Over $6 billionis spent annually in the US for asthmacare. ' Extensive researchcontinues to provide informationregarding basic mechanisms of airway inflammation.vClinical trials have shown that asthma outcomes can be dramatically improved with currently available medications along with other state-of-the-art management techniques. Where, then, is the profession of pharmacy in managing asthma? Are we initiating programsand publishingresults to document improved outcomes in asthma and other disease states? In addition, are we activeparticipants in multidisciplinary teams responsible for developing critical pathways or disease management guidelines, and monitoring various outcomes in acute care and ambulatory practice settings?
In the early 1990s, two clinical trials in the US6,7 demonstrated improved outcomes in patients with asthma when current management approaches were applied. Although these studies were conducted before the release of the 1991 National Institutes of Health (NIH) Guidelines for the Diagnosis and Management of Asthma,I they showed positive outcomes from application of principles of the guidelines. These trials involved a team of physicians and nurses to manage patients. Other recent studies focused on patienteducation to improveoutcomes, but were also performed by physician/nurse teams.Y A series of studies from Scotland have also examined strategies to improve outcomesin patientswith asthma. Since the releaseof the NIH Guidelines,I the subsequent International Report," and Global Initiative," a limited numberof studies have furtherdocumented that carefulapplication of these approaches to management improves outcomes. It is disappointing to note that a recent article" documentedwhat many of us observe in the clinical arena -practitioners frequently do not adhere to the NIH recommendations regardingthe use of inhaled antiinflammatory agents and patienteducation,and continue to rely too heavilyon symptomatic treatment.
Four trials have documented that pharmacists who initiate and manage asthma clinics improve outcomes.w" At the First National Conference on Asthma Management, which was organizedby the NIH NationalAsthma Education Program, two clinical trials initiated by pharmacists were presented as ongoing research." Both of these studies, which had the goal of reducingemergency department (ED) visits and hospitalizations in adult African-Americans, have subsequentlybeen published.w" Other studies by pharmacists were conducted at Kaiser Permanente in California" and a clinic in Florida for inner city patients with asthma."
One trial" took the innovative approach of educating indigent patients in the ED, since the ED is unfortunately the site of primary care for many of these patients, Many patients do not make clinic appointments after an ED visit, and it seemed logical to attempt to educate the patient and start long-term inhaled antiinflammatory therapy per the NIH Guidelines' while the patient might be more receptive (i.e., afraid because of currrentexacerbation). There was a 41% reduction in ED visits over 1 year after intervention, while a control group had no reduction in ED visits over the same period. Although the resultsof this study are suggestiveof a positiveimpact using this novel approach, further trialsare neededfor validation.
A secondstudy at the same institution also evaluatedthe effect of applying the principles of the NIH Guidelines'f in a clinic for working-or middle-class adult African-Americans over a 2-year period.IS As in the previoustrial," pharmacists initiated the clinic while working closely with a pulmonologist. Application of current management strate-
The Annals ofPharmacotherapy • 1997 April. Volume 31 • 495 gie~resulted in a 74% reduction in ED visits over 2 years, which was substantially greaterthan the 23% reduction in the control group. Emphasis was placed not onlyon tailoringeachpatient's drug regimen and detailed, persistent education, but alsoon active listening and ready accessibility as partof genuinely caring for the patient.
In a different setting, another pharmacist has shown very similar results after initiating an asthma clinic at KaiserPermanente.v Emphasizing patient education and monitoring, and using appropriate treatments, a reduction of 66% in ED visits and 48% in hospitalizations over 1 year was achieved. Patients and physicians were surveyed andexpressed very positive feelings aboutthe clinic.
Pauley et al." showed a dramatic reduction in ED visits by applying the NIH Guidelines' in a pharmacist-initiated and managed clinic for innercity minority patients in Jacksonville, FL. As in eachof the otherstudies cited, the phar-?1acist worked closely with physicians as well as patients m the clinic. The number of ED visits for 25 patients 6 months priorto enrollment was92 versus only6 visits during the 6 months of the clinic. For the same months of the yearpriorto the study, total ED visits were47.
Regarding efforts to improve outcomes in asthma by community pharmacists, we are awareof several ongoing "asthmacertificate programs." These intensive programs, emphasizing the NIH Guidelines and lasting 1-5 days depending on the sponsor, have the goal of giving pharmacists the knowledge and skill to documentimprovedoutcomes. Community pharmacists outside the US have documented efforts to enhance outcomes in patients with asthma."
Education and management programs have also shown improved outcomes in children withasthma. An education program led to increased knowledge of asthma and willingness to assumegreater responsibility for self care and total activity as well as decreased school absences, ED visits, and hospitalizations." Another studyproduced savings of $11.22 for every dollar spent on health education in children with asthma." Recently, an outpatient pediatric asthma management program in an independent practice association health maintenance organization led to improved outcomes and a savings of $2200/year for each child. The number of hospital days decreased 73%; hospital admissions 56%, ED visits 57%, and fee for service 48%.u Although pharmacists may have contributed to some degree in these pediatric studies, they were not coauthors. Pharmacists havea greatopportunity for improving patient care and reducing costs. For example, the projected costs of poorcompliance were$225000 due to unnecessary ED visits and hospitalizations in a group of 16children."
Whileeach of the outcomes studies by pharmacists is encouraging, further studies withlarge numbers of patients are needed in a variety of practice settings, including community pharmacies. Hospital-based pharmacists can participate in a multidisciplinary morning or afternoon clinic 'Yeekly. No singlememberof the healthcare team has thẽ me t~do all of the activities needed for optimal outcomes in panenrs with asthma. Most notably, once physicians agree to use the NIH Guidelines.!? the pharmacist is the ideal member of the team to take the necessary time to educate the patient to the level recommended and carefully tailor the drug regimen to achieveoptimal outcomes. An initial "loading dose" of education that takes 45 minutes to 1 houris extremely important, as is regular follow-up education. Analagous to prenatal care, early attention to patient education and overall management pays very large dividends, and failure to do so can havetragic results. It is gratifying that in threeof four pharmacist-authored trials, post-PharmD residents were investigators with their preceptors.tv-" Considering the rapid changes in the healthcare system and the urgent need to establish our value in the system, a significant percentage of pharmacy residents and fellows across the US should be trained in conducting outcomes research in various healthcare settings. Outcome measures have been incorporated within effie-acyZ4,15 and pharmacodynamics" studiesby pharmacy investigators.
Disease management guidelines and clinical pathways are being developed in many institutions and managed care organizations. The pharmacist should be an integral part of a multidisciplinary teamas theseguidelines are developed. Importantly, long-termfollow-up and outcomes measures should be incorporated within these guidelines, and the impact of theseguidelines on outcomes should be documented in the literature.
We look forward to further clinical outcomes trials in various diseases, initiated and managed by pharmacists in partnership with patients, physicians, and other healthcare practitioners. The time and energy invested in high-quality outcomes trials will offer great rewards, first for the patient, and also for the pharmacist, the profession, and the healthcare system.R o MC ZIP _
